Association of Plasma Retinol-Binding Protein 4, Adiponectin, and High Molecular Weight Adiponectin with Insulin Resistance in Non-Diabetic Hypertensive Patients
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to determine whether retinol-binding protein 4(RBP4), adiponectin and high molecular weight (HMW) adiponectin are associated with insulin resistance (IR) and metabolic parameters in non-diabetic hypertensive patients. Also, we sought to compare the predictive values of these adipocytokines for IR in non-diabetic hypertensive patients. Materials and Methods: Analyses of RBP4, adiponectin, and HMW adiponectin were performed on 308 non-diabetic hypertensives (148 males, age 58 ± 10 years, 189 non-metabolic syndrome and 119metabolic syndrome). The homeostasis model assessment (HOMA) index for IR,lipid profiles, and anthropometric measure-ments were assessed. Results: There was no significant difference in RBP4 levels according to the presence of metabolic syndrome, although adiponectin and HMW adiponectin were significantly lower in metabolic syndrome. Correlation analysis of log RBP4 with IR and metabolic indices revealed that there was no significant correlation of RBP4 with waist circumference (r = 0.056, p = 0.324), HDL cholesterol (r = 0.005, p = 0.934),ApoB/ApoAI ratio (r = 0.066, p = 0.270), and the HOMA index (r = 0.017, p =0.756). However, adiponectin and HMW adiponectin showed significant correlations with the HOMA index (r = - 0.247, p < 0.001; r = - 0.296, p < 0.001) and metabolic parameters. With IR defined as HOMA index ≥ 2.5, HMW adiponectin did not demonstrate a superior predictive value for IR compared to adiponectin (AUC = 0.680 vs. 0.648, p = 0.083). The predictive value of RBP4 for IR was minimal (AUC = 0.534). Conclusion: RBP4 was not associated with IR or metabolic indices and the predictive value for IR was minimal in hypertensives. HMW adiponectin didn’t have a superior predictive value for IR compared to adiponectin. Therefore, we can suggest that RBP4 and HMW adiponectin don’t have more additive information than adiponectin in non-diabetic hypertensives.
Abstract
Purpose: The aim of this study was to determine whether retinol-binding protein 4(RBP4), adiponectin and high molecular weight (HMW) adiponectin are associated with insulin resistance (IR) and metabolic parameters in non-diabetic hypertensive patients. Also, we sought to compare the predictive values of these adipocytokines for IR in non-diabetic hypertensive patients. Materials and Methods: Analyses of RBP4, adiponectin, and HMW adiponectin were performed on 308 non-diabetic hypertensives (148 males, age 58 ± 10 years, 189 non-metabolic syndrome and 119metabolic syndrome). The homeostasis model assessment (HOMA) index for IR,lipid profiles, and anthropometric measure-ments were assessed. Results: There was no significant difference in RBP4 levels according to the presence of metabolic syndrome, although adiponectin and HMW adiponectin were significantly lower in metabolic syndrome. Correlation analysis of log RBP4 with IR and metabolic indices revealed that there was no significant correlation of RBP4 with waist circumference (r = 0.056, p = 0.324), HDL cholesterol (r = 0.005, p = 0.934),ApoB/ApoAI ratio (r = 0.066, p = 0.270), and the HOMA index (r = 0.017, p =0.756). However, adiponectin and HMW adiponectin showed significant correlations with the HOMA index (r = - 0.247, p < 0.001; r = - 0.296, p < 0.001) and metabolic parameters. With IR defined as HOMA index ≥ 2.5, HMW adiponectin did not demonstrate a superior predictive value for IR compared to adiponectin (AUC = 0.680 vs. 0.648, p = 0.083). The predictive value of RBP4 for IR was minimal (AUC = 0.534). Conclusion: RBP4 was not associated with IR or metabolic indices and the predictive value for IR was minimal in hypertensives. HMW adiponectin didn’t have a superior predictive value for IR compared to adiponectin. Therefore, we can suggest that RBP4 and HMW adiponectin don’t have more additive information than adiponectin in non-diabetic hypertensives.
참고문헌 (29)
- Kannel WB, "Risk stratification in hypertension: new insights from the Framingham Study", Am J Hypertens, 13, pp.3S~10 (2000)
- Ansell BJ, "Evidence for a combined approach to the management of hypertension and dyslipidemia", Am J Hypertens, 18, pp.1249~1257 (2005)
- Wilson PW, "Clustering of metabolic factors and coronary heart disease", Arch Intern Med, 159, pp.1104~1109 (1999)
- Thomas F, "Cardiovascular mortality in hypertensive men according to presence of associated risk factors", Hypertension, 37, pp.1256~1261 (2001)
- Adamczak M, "Decreased plasma adiponectin concentration in patients with essential hypertension", Am J Hypertens, 16, pp.72~75 (2003)
- Iwashima Y, "Hypoadiponectinemia is an independent risk factor for hypertension", Hypertension, 43, pp.1318~1323 (2004)
- Baratta R, "Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies", J Clin Endocrinol Metab, 89, pp.2665~2671 (2004)
- Cnop M, "Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex", Diabetologia, 46, pp.459~469 (2003)
- Graham TE, "Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects", N Engl J Med, 354, pp.2552~2563 (2006)
- Lee DC, "Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents", Metabolism, 56, pp.327~331 (2007)
- Fisher FF, "Serum high molecular weight complex of adiponectin correlates better with glucose intolerance than total serum adiponectin in Indo-Asian males", Diabetalogia, 48, pp.1084~1087 (2005)
- Hara K, "Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome", Diabetes Care, 29, pp.1357~1362 (2006)
- Janke J, "Retinol binding protein 4 in human obesity", Diabetes, 55, pp.2805~2810 (2006)
- Broch M, "Circulating retinol binding protein-4, insulin sensitivity, insulin secretion and insulin disposition index in obese and nonobese subjects", Diabetes Care, 30, pp.1802~1806 (2007)
- Tan CE, "Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?", Diabetes Care, 27, pp.1182~1186 (2004)
- Jungner I, "Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials", Clin Chem, 44, pp.1641~1649 (1998)
- Jungner I, "Apolipoprotein B and A-I in relation to serum cholesterol and triglyceride in 43,000 Swedish males and females", Int J Lab Res, 21, pp.247~255 (1992)
- Yang Q, "Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes", Nature, 436, pp.356~362 (2005)
- Takashima N, "Retinol-binding protein 4 and insulin resistance", N Engl J Med, 355, pp.1392~ (2006)
- Tripathy D, "Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity", Diabetes Care, 27, pp.2204~2210 (2004)
- Stefan N, "High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans", Diabetes Care, 30, pp.1173~1178 (2007)
- Bowles WH, "Influence of insulin on liver vitamin A in rats", Diabetes, 16, pp.704~707 (1967)
- Sasaki H, "High retinol", retinol-binding protein ratio in non insulin-dependent diabetes mellitus, 1995, pp.310, 177~182
- Lara-Castro C, "Adiponectin multimeric complexes and the metabolic syndrome trait cluster", Diabetes, 55, pp.249~259 (2006)
- Blüher M, "Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays", Diabetes Care, 30, pp.280~285 (2007)
- Wang Y, "Post-translational modification of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex", J Biol Chem, 281, pp.16391~16400 (2006)
- Lee TS, "Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection", Circulation, 110, pp.1296~1302 (2004)
- Li M, "Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance", Diabetes, 57, pp.1526~1535 (2008)
- Nicolai A, "Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats", Hypertension, 53, pp.508~515 (2009)